Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.61 |
| ▸ | JAK2 | O60674 | 2/20 | 0.61 |
| ▸ | PRKAG1 | P54619 | 9/20 | 0.55 |
| ▸ | PRKAA1 | Q13131 | 9/20 | 0.55 |
| ▸ | PRKAB1 | Q9Y478 | 9/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.54 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
| ▸ | FER | P16591 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | MARK3 | P27448 | 1/20 | 0.54 |
| ▸ | FLT4 | P35916 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.54 |
| ▸ | CLK2 | P49760 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11015155 | 0.89 | JAK2 (0.51) | PDPK1JAK2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL261067 | 0.86 | IDO1 (0.62) | PDPK1JAK2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL30075258 | 0.86 | IDO1 (0.62) | PDPK1JAK2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL17039120 | 0.85 | JAK2 (0.64) | PDPK1JAK2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL9436096 | 0.85 | PDPK1 (0.59) | PDPK1JAK2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL4291226 | 0.81 | KDM4E (0.63) | PDPK1JAK2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL13386937 | 0.81 | YTHDC1 (0.63) | PDPK1JAK2DYRK1ADCLK1PRKD3 | |
| SCHEMBL21496911 | 0.81 | PDPK1 (0.54) | PDPK1JAK2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL26204518 | 0.81 | PDPK1 (0.58) | PDPK1JAK2DYRK1ADCLK1PRKD3 | |
| SCHEMBL1963463 | 0.81 | PRKAG1 (0.56) | PDPK1PRKAG1PRKAA1PRKAB1HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005082885-A1 | IMIDAZOLE BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-09 | — | — | WO | claimed |
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12486277-B2 | CDK inhibitors and their use as pharmaceuticals | Prelude Therapeutis Incorporated (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250243181-A2 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-07-31 | — | — | US | disclosed |
| EP-4585596-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Yingli Pharmaceutical Co., Ltd (CN) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025133961-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS FOR THE TREATMENT OF CHRONIC DISEASES | PFIZER INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12338230-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| WO-2025103409-A1 | NMT INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 南京同诺康医药科技有限公司 | 2025-05-22 | — | — | WO | disclosed |
| CN-1684962-A | Indazoles, benzothiazoles, and benzisothiazoles, and preparation and use thereof | MEMORY PHARM CORP (US) | 2005-10-19 | — | — | CN | disclosed |
| WO-2005092890-A2 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| CN-1656079-A | Pyrazole compounds and pharmaceutical compositions containing the same | EISAI CO LTD (JP) | 2005-08-17 | — | — | CN | disclosed |
| EP-1543000-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040132790-A1 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2004-07-08 | — | — | US | disclosed |
| WO-2004029050-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004029050-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | C5, DPYD, C9 | PDPK1 676/4885JAK2 1382/4885PRKAG1 2962/4885 |
| US-20040132790-A1 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | CHRNA5, CHRNA7, CHRNA3 | PDPK1 1949/4885JAK2 2278/4885PRKAG1 2169/4885 |
| US-12486277-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK3, CDK9 | PDPK1 179/4885JAK2 448/4885PRKAG1 346/4885 |
| US-12338230-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | PDPK1 1487/4885JAK2 1224/4885PRKAG1 4345/4885 |
| US-20250243181-A2 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | TRIB2, YAP1, IDO2 | PDPK1 1076/4885JAK2 2764/4885PRKAG1 2754/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | PDPK1 4006/4885JAK2 4305/4885PRKAG1 4785/4885 |
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDK9 | PDPK1 110/4885JAK2 262/4885PRKAG1 750/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | PDPK1 2921/4885JAK2 4719/4885PRKAG1 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.